Takara Bio launches industry-first CMO services for clinical-grade human embryonic stem cell derivation and banking
We are excited to be recognized in an article published by the stem cell industry blog BioInformant as the first company in the world to offer contract manufacturing services for the derivation and banking of human embryonic stem cells (hESCs) under GMP conditions. The cells are processed at Takara Bio's manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe's facility. With our new manufacturing license, we provide a safe, reliable source of hESCs for future cell therapy development by sourcing starting material from FDA-compliant facilities according to FDA guidelines and applying our feeder-free, xeno-free hESC establishment method. With our clinical-grade hES cell line derivation and cell banking services, we address an unmet need in the field for custom hESCs that can be used in the development of clinical cell therapy applications.
Read the full article: bioinformant.com/takara-bio
Back to Blog Front
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2026 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
